Santacruz Juan Camilo, Pulido Sandra, Arzuaga Angelo, Mantilla Marta Juliana, Santos Ana María, Londono John
Spondyloarthropathies Research Group, Universidad de La Sabana, Chía, COL.
Rheumatology Department, Universidad Militar Nueva Granada, Bogotá, COL.
Cureus. 2021 Dec 1;13(12):e20087. doi: 10.7759/cureus.20087. eCollection 2021 Dec.
In the current medical literature, there is increasing evidence for the involvement of the interleukin (IL)-17/23 axis and the potential role of Th17 cells in the pathogenesis of lupus nephritis. Knowledge about the interaction of these immunological pathways in the development of autoimmune diseases has led to the identification of new therapeutic strategies aimed at blocking them. For this reason, the main objective of this review focuses on knowing the recent evidence of the different anti-IL-17/23 treatment strategies in lupus nephritis and their future perspectives. A non-systematic narrative review of the literature was carried out following the objective of having the most representative information on the different anti-IL-17/23 drugs available together with the description of the pathophysiological mechanisms of this pathway involved in systemic lupus erythematosus and lupus nephritis. Despite the great existing theoretical foundation, today few clinical studies support the use of these therapies in both contexts. Nevertheless, the publication of research with a better methodology is expected to approve the indication of some of these drugs in lupus nephritis. However, the clinical response seen with ustekinumab and secukinumab in clinical studies and case reports published to date has been encouraging.
在当前的医学文献中，越来越多的证据表明白细胞介素（IL）-17/23轴以及Th17细胞在狼疮性肾炎发病机制中的潜在作用。关于这些免疫途径在自身免疫性疾病发展过程中相互作用的认识，促使人们确定了旨在阻断它们的新治疗策略。因此，本综述的主要目标是了解狼疮性肾炎中不同抗IL-17/23治疗策略的最新证据及其未来前景。为了获取有关不同抗IL-17/23药物最具代表性的信息，并描述该途径参与系统性红斑狼疮和狼疮性肾炎的病理生理机制，我们对文献进行了非系统性的叙述性综述。尽管现有的理论基础很雄厚，但目前很少有临床研究支持在这两种情况下使用这些疗法。不过，预计采用更好方法开展的研究会批准其中一些药物用于狼疮性肾炎的适应证。然而，迄今为止在临床研究和病例报告中观察到的优特克单抗和司库奇尤单抗的临床反应令人鼓舞。
